ISRCTN57354520 https://doi.org/10.1186/ISRCTN57354520

# Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

| | | |
|---|---|---|
| **Submission date**<br>21/02/2006 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[_] Record updated in last year |
| **Registration date**<br>29/03/2006 | **Overall study status**<br>Completed | |
| **Last Edited**<br>10/07/2017 | **Condition category**<br>Circulatory System | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr Narasimharajapura Rajendra

**Contact details**
Department of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
RAJ001

# Study information

### Scientific Title
Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

### Study objectives
Allopurinol, by inhibiting xanthine oxidase brings about a reduction in reactive oxygen species, thereby preventing adverse remodelling

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Regional Ethics Committee, 07/12/2005, ref: 05/S1401/171

### Study design
Randomised double-blind placebo-controlled parallel group

### Primary study design
Interventional

### Secondary study design
Randomised parallel trial

### Study setting(s)
Hospital

### Study type(s)
Treatment

### Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

### Health condition(s) or problem(s) studied
Myocardial infarction

### Interventions
Allopurinol versus placebo

### Intervention Type
Drug

### Phase
Not Applicable

### Drug/device/biological/vaccine name(s)
Allopurinol

### Primary outcome measure

Assessment of remodelling

### Secondary outcome measures
Brain natriuretic peptide (BNP)

### Overall study start date
10/02/2006

### Completion date
02/04/2008

## Eligibility

### Key inclusion criteria
Post myocardial infarction - days 3 to 14

### Participant type(s)
Patient

### Age group
Adult

### Sex
Both

### Target number of participants
36

### Key exclusion criteria
1. Renal failure
2. Concomitant warfarin therapy
3. Allopurinol allergy

### Date of first enrolment
10/02/2006

### Date of final enrolment
02/04/2008

## Locations

### Countries of recruitment
Scotland

United Kingdom

### Study participating centre

**Ninewells Hospital**
Dundee
United Kingdom
DD1 9SY

# Sponsor information

**Organisation**
University of Dundee (UK)

**Sponsor details**
The Nethergate
University of Dundee
Dundee
Scotland
United Kingdom
DD1 4HN

**Sponsor type**
University/education

**ROR**
https://ror.org/03h2bxq36

# Funder(s)

**Funder type**
Charity

**Funder Name**
British Heart Foundation

**Alternative Name(s)**
the_bhf, The British Heart Foundation, BHF

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**
Trusts, charities, foundations (both public and private)

**Location**
United Kingdom

# Results and Publications

### Publication and dissemination plan
Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary
Not provided at time of registration